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Most germ-cell tumors (GCTs) are located in the gonads,
although about 2–5% arise from extragonadal regions, such
as the mediastinum, retroperitoneum, and central nervous
system [1,2]. Though gonadal and extragonadal GCTs share
similar histologic characteristics and genetic abnormalities,
extragonadal GCTs are clinically and biologically distinct
from their testicular counterparts [3–5]. The mediastinum is
the most common site of primary extragonadal GCTs, and
GCTs represent approximately 10–15% of mediastinal
tumors [1,6]. It has been suggested that these tumors are
derived from primitive germ cells that either mismigrate
along the urogenital ridge during early embryogenesis, or
are distributed physiologically to the liver, bone marrow,
and brain to provide regular functions [7,8].
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Primary mediastinal GCTs without gonadal involvement
are rare [1,6]. They can be divided into benign mature
teratoma and malignant seminoma or nonseminoma.
Though the outcome of mature teratoma seems good after
surgical intervention, the prognosis of malignant GCTs in
the mediastinum is not fully understood, especially that of
nonseminomas [9–11]. The situation has shown some
improvement since the introduction of platinum-based and
high-dose chemotherapy [12–14]. However, the outcome is
still poor and there is little data concerning Asian
populations. In this study, we describe our experience of
malignant mediastinal GCTs and compare the presentations
and outcome with those of benign teratoma.
MATERIALS AND METHODS
Pathology reports from Kaohsiung Medical University
Hospital for 1992–2004 were reviewed to find primary
mediastinal GCTs. Four malignant GCTs and nine mature
teratomas were found and included in this study.
© 2005 Elsevier. All rights reserved.
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Clinical presentation, treatment course, and outcome, were
retrospectively analyzed.
Diagnostic  imaging studies, including chest
radiography and computed tomography (CT), were used
to confirm the mediastinal mass. Serum tumor markers,
including _-fetoprotein (AFP) and `-human chorionic
gonadotropin (`HCG), were also checked in some patients.
In male patients, normal testes were confirmed by physical
examination and ultrasound. Histologic diagnosis was
based on the World Health Organization classification
criteria [1,15].
RESULTS
Characteristics
Nine cases of benign mature teratoma and four of malignant
GCT, including one seminoma, one choriocarcinoma, and
two yolk-sac tumors, were included in this study (Table).
Among these cases, there were seven male and six female
patients with a median age of 24 years (range, 1–44 yrs).
Compared with benign teratomas, which occurred across a
wide age range, all four malignant GCTs were in adult
males. Most patients (69.2%) had symptoms and signs
before diagnosis. All malignant GCTs had symptoms,
including superior vena cava (SVC) syndrome, severe
dyspnea and chest pain, but only five of the nine patients
with benign teratomas showed symptoms. No elevation of
tumor markers was found in patients with teratomas and
the seminoma, while high HCG levels were noted in the
patient with choriocarcinoma. High AFP levels were noted
in the two cases of yolk-sac tumor.
Treatment and outcome
All patients with teratomas underwent surgical intervention
for total tumor removal without further management. The
outcomes were good in these patients, with no therapy-
related mortality. However, multiple modalities of treatment
were prescribed for malignant GCTs. The patient with
seminoma underwent surgery for total tumor removal,
followed by radiation, and had a good outcome. The two
patients with yolk-sac tumors underwent surgery initially,
but total tumor removal was not possible. Six courses of
chemotherapy with cisplatin, bleomycin, and etoposide
were prescribed immediately after surgery. The patient
with choriocarcinoma also received cisplatin-based
chemotherapy immediately after diagnosis due to multiple
lung metastasis, with no obvious response.
Table. Characteristics of malignant and benign germ-cell tumors
Diagnosis (n = 13) Malignant (n = 4) Benign (n = 9)
Mature teratoma 9
Seminoma 1
Yolk-sac tumor 2
Choriocarcinoma 1
Median age 23.5 years 20.0 years
Gender
Male 4 3
Female 0 6
Symptoms
9 (69.2%) 4 (100%) 5 (55.6%)
Treatment
Surgery alone 9
Surgery + radiation 1 seminoma
Surgery + chemotherapy 2 yolk-sac tumors
Chemotherapy only 1 choriocarcinoma
Outcome (median follow-up, 8 yrs)
Death 2 (50%) 0
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Compared with malignant GCTs, teratomas had good
prognosis without mortality or recurrence (Figure). There
were two deaths in the median follow-up of 8 years, one in
the choriocarcinoma patient with multiple lung metastasis
and no response to chemotherapy, and one in a patient with
yolk-sac tumor who did not achieve complete response,
as shown by imaging and tumor marker levels after
chemotherapy. The second patient suffered from disease
recurrence within 1 year without response to salvage
chemotherapy and eventually died. Compared with this
case of yolk-sac tumor, the other had normal levels of AFP
and no residual tumor after chemotherapy, as shown by
imaging studies. He had stable disease without recurrence
for more than 2 years. The patient with seminoma had a
better outcome than other patients with malignant GCTs,
with no evidence of disease after management.
DISCUSSION
We retrospectively analyzed cases of primary mediastinal
GCTs and compared malignant GCTs with benign
teratomas. There were nine benign teratomas (69.2%) and
four malignant GCTs (30.8%), including one seminoma and
three nonseminomas. The frequency of malignancy was
similar to that in Japan [5,16], but slightly lower than that in
the USA (39.4%) and Europe (40.8%) [17–19]. There were
some differences in clinical characteristics between benign
teratomas and malignant GCTs. For example, there was an
overwhelming male predominance in malignant GCTs,
while in benign teratoma, females outnumbered males.
This is the same as in other reports, which show strong
male predominance in malignant GCTs, with a near-
equivalent sex ratio or a mild female preponderance in
patients with benign teratoma [5,6,9,11,20]. In the malignant
group, all patients were young adults without children,
while in the benign teratoma group, there were three
children and one adult aged 44 years, as well as five young
adults. In addition, high levels of tumor markers were
noted in the malignant GCTs, especially in patients with
nonseminomas, while no obvious elevation was found in
patients with benign teratomas.
The outcome of malignant GCTs was poor, compared
with that of mature teratoma, and nonseminomas had the
worst prognosis. Cisplatin-based chemotherapy has recently
been shown to improve survival in malignant GCTs [5,9,12,
13]. However, both of the deaths in our study occurred in
patients who had received chemotherapy. The death of the
patient with choriocarcinoma, who died from respiratory
failure, may have been due to the extended multiple
pulmonary metastasis. The other death occurred in a patient
with yolk-sac tumor without normalized AFP after surgical
intervention and chemotherapy, who suffered from relapse
of disease within 1 year and died from progressive disease.
Figure. Survival curves of patients with primary mediastinal germ-cell tumor (GCT). (A) Compared with mature teratoma, malignant GCTs had
a poor prognosis. (B) Of malignant GCTs, nonseminomas had a poorer outcome than seminoma, even after treatment.
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The other patient with yolk-sac tumor had complete response
and normalized AFP after treatment, and was alive for 2
subsequent years. These two deaths highlight the important
role of extended disease and tumor marker levels in surviving
patients [9,11]. In addition to improvements in chem-
otherapy, high-dose chemotherapy with hematopoietic
progenitor cell support shows promise in malignant GCTs
with poor risk [5,11,13,14]. Further studies are needed to
draw a final conclusion about novel therapies in malignant
mediastinal GCTs.
For many years, radiation therapy has been either the
primary therapy or one of a combination of therapies after
surgery, due to the unique radiosensitive characteristics of
seminoma [1,2,21]. Recently, chemotherapy has been
introduced into the treatment modalities of seminoma,
especially at advanced stages, with good response, while
the role of surgical resection is changing [5,10,22]. However,
it has also been suggested that patients with mediastinal
seminoma have an excellent outcome regardless of treatment
approach [23].
In summary, we have reported our experience of
malignant mediastinal GCTs. Benign mature teratomas and
the seminoma had good response and long-term survival.
However, three nonseminomas had poor outcome with
two deaths. The poor outcome of malignant cases highlights
the important role of advanced disease and tumor-marker
levels in survival. Though cisplatin-based chemotherapy
improves survival in malignant mediastinal GCTs, new
strategies for malignant cases await investigation in the
hope of improved survival.
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